Biotech pain continues as Versant, MPM gene therapy startup calls it quits
A gene therapy startup backed by two key biopharmas and two premier biotech VC firms has ceased operations.
California biotech Coda Biotherapeutics shut down recently, investors Versant Ventures and MPM Capital confirmed to Endpoints News Tuesday night, declining to provide further details. The upstart had presented preclinical data on its program for focal epilepsy last summer but had not provided an update since then. MPM removed Coda from its portfolio page in recent weeks, per internet archives, and the biotech’s LinkedIn page has been wiped.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.